Author:
Barata F.,Queiroga H.,Teixeira E.,Almodovar T.,Soares M.,Parente B.,Mellidez J.C.,Alves P.,Antunes A.
Subject
Pulmonary and Respiratory Medicine
Reference7 articles.
1. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up;D’Addario;Ann Oncol,2008
2. Clinical characteristics and survival outcomes for non-small-cell lung cancer patients with epidermal growth factor receptor double mutations;Peng;Biomed Res Int,2018
3. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study;Cappuzzo;Lancet Oncol,2010
4. Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: a multicenter academic phase II STUDY in Caucasian patients (FIELT);De Greve;PLoS One,2016
5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011